trending Market Intelligence /marketintelligence/en/news-insights/trending/GsVHx0EyZa7H8A9qpCAQLQ2 content esgSubNav
In This List

Immunotec fiscal Q3 profit falls YOY

Blog

Gold - Geopolitical tensions and inflation remain key drivers

Blog

Lithium and Cobalt - Softer demand weighs on prices

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds


Immunotec fiscal Q3 profit falls YOY

Immunotec Inc. said its normalized net income for the fiscal third quarter ended July 31 was C$523,100, a decline of 38.5% from C$850,700 in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin fell to 1.8% from 3.9% in the year-earlier period.

Total revenue climbed 28.6% year over year to C$28.4 million from C$22.1 million, and total operating expenses rose 33.0% on an annual basis to C$27.6 million from C$20.8 million.

Reported net income declined 46.6% on an annual basis to C$629,600, or 1 cents per share, from C$1.2 million, or 2 cents per share.